Trials / Completed
CompletedNCT00946673
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorinostat | Orally up to 400 mg |
| PROCEDURE | Radiation Therapy | Single fraction stereotactic radiotherapy - Standard of Care |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2014-07-01
- Completion
- 2015-07-01
- First posted
- 2009-07-27
- Last updated
- 2017-10-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00946673. Inclusion in this directory is not an endorsement.